H
Hagop Youssoufian
Researcher at ImClone Systems
Publications - 50
Citations - 8495
Hagop Youssoufian is an academic researcher from ImClone Systems. The author has contributed to research in topics: Cetuximab & Cancer. The author has an hindex of 20, co-authored 43 publications receiving 7862 citations. Previous affiliations of Hagop Youssoufian include University of Colorado Denver & Eli Lilly and Company.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner,Paul M. Harari,Jordi Giralt,Nozar Azarnia,Dong M. Shin,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,Jacek Jassem,Roger Ove,Merrill S. Kies,José Baselga,Hagop Youssoufian,Nadia Amellal,Eric K. Rowinsky,Eric K. Rowinsky,K. Kian Ang +17 more
TL;DR: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Journal ArticleDOI
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
James A. Bonner,Paul M. Harari,Jordi Giralt,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,José Baselga,Sharon A. Spencer,Junming Zhu,Hagop Youssoufian,Eric K. Rowinsky,K. Kian Ang +12 more
TL;DR: Overall survival was significantly improved in those who experienced an acneiform rash of at least grade 2 severity compared with patients with no rash or grade 1 rash, confirming cetuximab plus radiotherapy as an important treatment option in this group of patients.
Journal ArticleDOI
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
Jennifer L. Spratlin,Roger B. Cohen,Matthew Eadens,Lia Gore,D. Ross Camidge,Sami Diab,Stephen Leong,Cindy L. O'Bryant,Laura Q.M. Chow,Natalie J. Serkova,N. J. Meropol,Nancy L. Lewis,E. Gabriela Chiorean,Floyd Fox,Hagop Youssoufian,E. K. Rowinsky,S. Gail Eckhardt +16 more
TL;DR: Objective antitumor activity and antiangiogenic effects were observed over a wide range of dose levels, suggesting that ramucirumab may have a favorable therapeutic index in treating malignancies amenable to VEGFR-2 inhibition.
Journal ArticleDOI
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.
Daniel D. Von Hoff,Monica M. Mita,Ramesh K. Ramanathan,Glen J. Weiss,Alain C. Mita,Patricia LoRusso,Howard A. Burris,Lowell L. Hart,Susan C. Low,Donald Parsons,Stephen E. Zale,Jason Summa,Hagop Youssoufian,Jasgit C. Sachdev +13 more
TL;DR: BIND-014 demonstrated a dose-linear pharmacokinetic profile, distinct from docetaxel, with prolonged persistence of docetAXel-encapsulated circulating nanoparticles, which was generally well tolerated and predictable and manageable toxicity.
Journal ArticleDOI
IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
Eric K. Rowinsky,Hagop Youssoufian,James R. Tonra,Phillip Solomon,Douglas Burtrum,Dale L. Ludwig +5 more
TL;DR: Although promising single-agent activity has been observed, the most impressive effects of targeting the IGF-IR with IMC-A12 have been noted when this agent was combined with cytotoxic agents or other targeted therapies.